Glaukos to acquire DOSE Medical for $2.5M plus milestones

Glaukos Corporation entered into a definitive agreement to acquire DOSE Medical Corporation for $2.5 million in cash plus performance-based consideration. DOSE Medical develops sustained-release drug delivery platforms for retinal diseases. The transaction is expected to close in the current quarter.

“With this acquisition, Glaukos will establish a new R&D retinal program that complements our growing glaucoma franchise and pipeline.”investors.glaukos.com

• 1 source
• investors.glaukos.comGlaukos Corporation - Glaukos Corporation Enters into Definitive Agreement to Acquire DOSE Medical CorporationJun 19, 2019

Summarized from public sources; check the original articles before acting on it.